First-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer

被引：0

作者：

Sharma, Manish

Strickler, John H.

Sommerhalder, David

Kuboki, Yasutoshi

Perets, Ruth

Cohen, Jonathan

Raimbourg, Judith

Nakajima, Takako Eguchi

Yamamoto, Noboru

Cruz-Correa, Marcia

O'Neil, Bert

Ghiringhelli, Francois

Raghav, Kanwal Pratap Singh

Li, Rui

Thiele, Gladys Morrison

Aristide, Martha Raluca Neagu

Freise, Kevin Jay

de Almeida, Carla Biesdorf

Vasilopoulos, Athanasios

Powderly, John D., II

机构：

[1] START Midwest, Grand Rapids, MI USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] NEXT Oncol, San Antonio, TX USA

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Rambam Med Ctr, Haifa, Israel

[6] Technion Israel Inst Technol, Haifa, Israel

[7] Hebrew Univ Jerusalem, Sharett Inst Oncol, Wohl Inst Translat Med, Hadassah Med Ctr,Hadassh Hebrew Univ Med Ctr, Jerusalem, Israel

[8] Ctr Rene Gauducheau, Insit Cancerol Ouest, St Herblain, France

[9] Kyoto Univ, Grad Sch Med, Kyoto, Japan

[10] Natl Canc Ctr, Tokyo, Japan

[11] Univ Puerto Rico, Med Sci Campus, San Juan, PR USA

[12] Pan Amer Ctr Oncol Trials, San Juan, PR USA

[13] Community Hlth Canc Ctr North, Indianapolis, IN USA

[14] Ctr Georges Francois Leclerc, Dijon, France

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[16] AbbVie Inc, N Chicago, IL USA

[17] Carolina Biooncol Inst, Huntersville, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3515

引用

页数：1

共 50 条

[41] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Hassan, Raffit
Blumenschein, George R., Jr.
Moore, Kathleen N.
Santin, Alessandro D.
Kindler, Hedy L.
Nemunaitis, John J.
Seward, Shelly M.
Thomas, Anish
Kim, Stella K.
Rajagopalan, Prabhu
Walter, Annette O.
Laurent, Dirk
Childs, Barrett H.
Sarapa, Nenad
Elbi, Cem
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
[42] Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Chandana, S.
Garmezy, B.
Dowlati, A.
Sharma, M. R.
Henner, W.
Robinson, R.
Hingorani, P.
Jeng, E.
Papadopoulos, K. P.
ANNALS OF ONCOLOGY, 2023, 34 : S1077 - S1077
[43] First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Vij, Ravi
Nath, Rajneesh
Afar, Daniel E. H.
Mateos, Maria Victoria
Berdeja, Jesus G.
Raab, Marc S.
Guenther, Andreas
Martinez-Lopez, Joaquin
Jakubowiak, Andrzej J.
Leleu, Xavier
Weisel, Katja
Wong, Shekman
Gulbranson, Scott
Sheridan, James P.
Reddy, Anita
Paiva, Bruno
Singhal, Anil
San-Miguel, Jesus F.
Moreau, Philippe
CLINICAL CANCER RESEARCH, 2020, 26 (10) : 2308 - 2317
[44] Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.
Calvo, Emiliano
Cleary, James M.
Moreno, Victor
Gifford, Maryella
Roberts-Rapp, Lisa
Ansel, Peter J.
Mittapalli, Rajendar K.
Lee, Ho-jin
Hu, Beibei
Barch, David
Ocampo, Christopher Joseph
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[45] BYON3521, a novel effective and safe c-Met targeting antibody-drug conjugate.
Groothuis, Patrick
Jacobs, Danielle
Hermens, Inge
Damming, Desiree
Mattaar, Ellen
Rouwette, Myrthe
van der Vleuten, Monique
Sesink, Aloys
Dijcks, Fred
Coumans, Ruud
Blomenrohr, Marion
Ubink, Ruud
van der Lee, Miranda
Dokter, Wim H. A.
CANCER RESEARCH, 2021, 81 (13)
[46] Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers
Ko, Andrew H.
Coveler, Andrew L.
Schlechter, Benjamin L.
Bekaii-Saab, Tanios S.
Wolpin, Brian M.
Clark, Jeffrey William
Cheng, Yi-Lin
Cheng, Ting-Ying
Langecker, Peter J.
Lin, Shih-Yao
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[47] Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
Meric-Bernstam, F.
Naito, Y.
Gaillard, S.
Shimoi, T.
Chung, V.
Davis, A. A.
Proia, T.
Ayyoub, A.
Kulkarni, M.
Upadhyay, S.
Miller, N.
Luheshi, N.
Varga, A.
Oh, D-Y.
Mileshkin, L.
ANNALS OF ONCOLOGY, 2024, 35 : S485 - S486
[48] A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.
Aftimos, Philippe G.
Barthelemy, Philippe
Rolfo, Christian D.
Hanssens, Valerie
De Jonge, Natalie
Silence, Karen
Dreier, Torsten
de Haard, Hans
Peeters, Marc
Thibault, Alain
Awada, Ahmad
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
Kim, Richard
Leal, Alexis D.
Parikh, Aparna
Ryan, David P.
Wang, Shining
Bahamon, Brittany
Gupta, Neeraj
Moss, Aaron
Pye, Joanna
Miao, Harry
Inguilizian, Haig
Cleary, James M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (04) : 291 - 300
[50] CKD-703, a novel antibody-drug conjugate targeting cMET with an enhanced therapeutic index in solid tumors
Lee, Kwanwoo
Kim, Sue-Youn
Hong, Hye-Jin
Park, Eunjeong
Park, Jungok
Hong, Seong-Ho
Bae, Daekwon
Ha, Nina
Yeon, Sohn-Ji
Hwang, Inchang
Kim, Semi
Lee, Yoonseok
Lee, Ju-Hee
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 4 5 →